DermTech Reports First-Quarter 2024 Financial Results
DermTech (NASDAQ: DMTK) reported its Q1 2024 financial results, highlighting a 7% increase in test revenue to $3.7 million and an 11% rise in total revenue to $3.8 million, attributed to higher average selling prices. Despite a 14% decline in billable sample volume, cost of test revenue decreased by 19%, improving the test gross margin to 16%. Sales, marketing, R&D, and general administrative expenses saw significant reductions, contributing to a net loss of $20.0 million ($0.58 per share), a notable improvement from Q1 2023's $31.3 million loss ($1.02 per share). The company had $42.4 million in cash and equivalents as of March 31, 2024.
- Test revenue increased by 7% to $3.7 million compared to Q1 2023.
- Total revenue grew by 11% to $3.8 million.
- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased by 24% year-over-year.
- Cost of test revenue decreased by 19%, improving the test gross margin to 16%.
- Sales and marketing expenses decreased by 49%.
- Research and development expenses were reduced by 26%.
- General and administrative expenses fell by 15%.
- Net loss improved to $20.0 million ($0.58 per share) from $31.3 million ($1.02 per share) in Q1 2023.
- Cash, cash equivalents, restricted cash, and short-term marketable securities totaled $42.4 million as of March 31, 2024.
- Billable sample volume declined by 14% compared to Q1 2023.
- Net loss was $20.0 million, indicating the company is still operating at a loss.
- The first quarter included a $1.3 million non-recurring restructuring charge.
- Employee-related costs, although reduced, indicate potential downsizing.
Insights
DermTech's first-quarter results show a complex picture for investors. On the positive side, the average selling price (ASP) of their key product, the DermTech Melanoma Test (DMT), has increased by
However, the billable sample volume declined by
Despite the volume decline, test revenue increased by
Noteworthy is the significant reduction in expenses, including a
However, the company still reported a net loss of
The increase in ASP and test revenue signifies that DermTech's product is gaining traction in the market, potentially reflecting higher perceived value among customers. This can be a positive indicator for future revenue streams.
However, the decline in billable sample volume is a red flag. This could be due to competitive dynamics, market saturation, or issues with customer acquisition strategies. It's important for DermTech to investigate and address the reasons behind this decline to ensure sustainable growth.
The considerable reduction in sales, marketing and R&D expenses shows that the company is focusing on cost control, which is a prudent move in the face of mounting net losses. However, these cuts must be balanced with efforts to drive growth and innovation, as under-investment in these areas could hinder long-term competitiveness and market presence.
Overall, while DermTech is making strides in cost management and improving revenue metrics, the decline in sample volume and ongoing net losses indicate that the company still faces significant challenges.
- Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year
- Test revenue increased 7 percent versus the first quarter of 2023
First-Quarter 2024 Financial Results
- Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360.
-
Test revenue was
$3.7 million -
Total revenue was
$3.8 million -
Cost of test revenue was
$3.1 million -
Sales and marketing expenses were
$7.8 million -
Research and development expenses were
$3.3 million -
General and administrative expenses were
$10.1 million $1.3 million -
Net loss was
$20.0 million $0.58 $2.7 million $31.3 million $1.02 $4.7 million -
Cash, cash equivalents, restricted cash and short-term marketable securities were
$42.4 million
About DermTech
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics technology. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected using its Smart StickersTM. DermTech develops and markets products that facilitate the assessment of melanoma. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “explore,” “estimate,” “project,” “budget,” “forecast,” “aim,” “runway,” “outlook,” “anticipate,” “intend,” “plan,” “strive,” “may,” “will,” “sustain,” “remain,” “continue,” “could,” “should,” “believe,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations, evaluations and other statements with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products; expectations regarding DermTech’s financial outlook, including its cash runway, future financial performance and ability to reduce cost, expenses and cash burn, including as a result of DermTech’s restructuring plan; and the prospects for DermTech’s review and evaluation of potential strategic alternatives; and the terms, timing, structure, benefits and costs of any strategic transaction and whether one will be consummated at all. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional capital when and as needed or on acceptable terms or its ability to complete a strategic transaction, the failure of which may result in DermTech having to further curtail its operations, liquidate or otherwise dispose of assets, wind-down or cease operations entirely, any of which may result in stockholders receiving limited or no value for their investment; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by government payers (including Medicare) and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to manage its existing and potential future operations (including with respect to processing test orders), retain its key employees, maintain or improve its operating efficiency and reduce operating expenses, including, in each case, after the restructuring actions are complete; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; (9) the potential outcome and timing of DermTech’s announced process to explore strategic alternatives, including the potential that no such transaction will be completed in a timely manner or at all or that such a transaction will result in significant or any value to stockholders; (10) DermTech’s ability to continue as a going concern and (11) other risks and uncertainties included in the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
DERMTECH, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited) |
||||||||
|
Three Months Ended March 31, |
|
||||||
|
|
2024 |
|
|
|
2023 |
|
|
Revenues: |
|
|
|
|
||||
Test revenue |
$ |
3,677 |
|
|
$ |
3,425 |
|
|
Contract revenue |
|
168 |
|
|
|
52 |
|
|
Total revenues |
|
3,845 |
|
|
|
3,477 |
|
|
Cost of revenues: |
|
|
|
|
||||
Cost of test revenue |
|
3,085 |
|
|
|
3,791 |
|
|
Cost of contract revenue |
|
47 |
|
|
|
30 |
|
|
Total cost of revenues |
|
3,132 |
|
|
|
3,821 |
|
|
Gross profit/(loss) |
|
713 |
|
|
|
(344 |
) |
|
Operating expenses: |
|
|
|
|
||||
Sales and marketing |
|
7,817 |
|
|
|
15,417 |
|
|
Research and development |
|
3,266 |
|
|
|
4,409 |
|
|
General and administrative |
|
10,138 |
|
|
|
11,875 |
|
|
Total operating expenses |
|
21,221 |
|
|
|
31,701 |
|
|
Loss from operations |
|
(20,508 |
) |
|
|
(32,045 |
) |
|
Other income: |
|
|
|
|
||||
Interest income, net |
|
498 |
|
|
|
782 |
|
|
Change in fair value of warrant liability |
|
— |
|
|
|
(7 |
) |
|
Total other income |
|
498 |
|
|
|
775 |
|
|
Net loss |
$ |
(20,010 |
) |
|
$ |
(31,270 |
) |
|
Weighted average shares outstanding used in computing net loss per share, basic and diluted |
|
34,706,491 |
|
|
|
30,557,216 |
|
|
Net loss per share of common stock outstanding, basic and diluted |
$ |
(0.58 |
) |
|
$ |
(1.02 |
) |
|
DERMTECH, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (Unaudited) |
|||||||
|
March 31, 2024 |
|
December 31, 2023 |
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
27,579 |
|
|
$ |
36,741 |
|
Short-term marketable securities |
|
11,400 |
|
|
|
19,123 |
|
Accounts receivable |
|
2,497 |
|
|
|
2,584 |
|
Inventory |
|
831 |
|
|
|
1,004 |
|
Prepaid expenses and other current assets |
|
1,892 |
|
|
|
2,300 |
|
Total current assets |
|
44,199 |
|
|
|
61,752 |
|
Property and equipment, net |
|
4,498 |
|
|
|
4,988 |
|
Operating lease right-of-use assets |
|
50,806 |
|
|
|
51,722 |
|
Restricted cash |
|
3,467 |
|
|
|
3,468 |
|
Total assets |
$ |
102,970 |
|
|
$ |
121,930 |
|
Liabilities and Stockholders’ Equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
1,913 |
|
|
$ |
1,484 |
|
Accrued compensation |
|
5,248 |
|
|
|
6,664 |
|
Accrued liabilities |
|
1,943 |
|
|
|
2,017 |
|
Short-term deferred revenue |
|
203 |
|
|
|
196 |
|
Current portion of operating lease liabilities |
|
3,194 |
|
|
|
3,069 |
|
Current portion of finance lease obligations |
|
17 |
|
|
|
17 |
|
Total current liabilities |
|
12,518 |
|
|
|
13,447 |
|
|
|
|
|
||||
Long-term finance lease obligations, less current portion |
|
34 |
|
|
|
38 |
|
Operating lease liabilities, long-term |
|
50,424 |
|
|
|
51,270 |
|
Total liabilities |
|
62,976 |
|
|
|
64,755 |
|
Stockholders’ equity: |
|
|
|
||||
Common stock, |
|
3 |
|
|
|
3 |
|
Additional paid-in capital |
|
483,752 |
|
|
|
480,929 |
|
Accumulated other comprehensive income |
|
184 |
|
|
|
178 |
|
Accumulated deficit |
|
(443,945 |
) |
|
|
(423,935 |
) |
Total stockholders’ equity |
|
39,994 |
|
|
|
57,175 |
|
Total liabilities and stockholders’ equity |
$ |
102,970 |
|
|
$ |
121,930 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514048042/en/
Steve Kunszabo
DermTech
(858) 291-1647
steve.kunszabo@dermtech.com
Source: DermTech, Inc.
FAQ
What was DermTech's total revenue for Q1 2024?
How much did the DermTech Melanoma Test (DMT) average selling price increase?
What was the test revenue for DermTech in Q1 2024?
How did DermTech's billable sample volume change in Q1 2024?
What was DermTech's net loss in Q1 2024?
How much cash and cash equivalents did DermTech have as of March 31, 2024?
What were DermTech's sales and marketing expenses for Q1 2024?
How much did DermTech's research and development expenses decrease in Q1 2024?
